Meike Ressing
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Meike Ressing has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Adam Gondos
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany
1 shared publication - Alexander Katalinic
Institute of Social Medicine and Epidemiology, University of Luebeck, Luebeck, Germany
1 shared publication - Bernd Holleczek
Saarland Cancer Registry, 66024 Saarbrücken, Germany
1 shared publication - Hermann Brenner
Cancer Prevention Graduate School, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
1 shared publication - Lina Jansen
Division of Clinical Epidemiology and Aging Research, DKFZ, Heidelberg, Germany
1 shared publication The GEKID Cancer Survival Working Group
1 shared publication
Latest Publications
- Open Access
- 30 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 1-9
Survival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage
Population-based studies on endometrial cancer providing survival estimates by age, histology, and stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial cancer patients in Germany. We used a pooled German national dataset including data from 11 cancer registries covering a population of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included. Period analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was observed, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years. Furthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from 43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for distant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent 5-year period under investigation. In this comprehensive population-based survival analysis of patients with endometrial cancer from Germany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage. While prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer patients has been stagnating in the early 21st century.
- 30 March 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 1-9
Open AccessSurvival of endometrial cancer patients in Germany in the early 21st century: a period analysis by age, histology, and stage
Population-based studies on endometrial cancer providing survival estimates by age, histology, and stage have been sparse. We aimed to derive most up-to-date and detailed survival estimates for endometrial cancer patients in Germany. We used a pooled German national dataset including data from 11 cancer registries covering a population of 33 million people. 30,906 patients diagnosed with endometrial cancer in 1997-2006 were included. Period analysis was performed to calculate 5-year relative survival (RS) in 2002-2006. Trends in survival between 2002 and 2006 were examined using model-based period analysis. Age-adjustment was performed using five age groups (15-44, 45-54, 55-64, 65-74, and 75+ years). Overall, age-adjusted 5-year relative survival in 2002-2006 was 81%. A moderate age gradient was observed, with 5-year RS decreasing from 90% in the age group 15-49 years to 75% in the age group 70+ years. Furthermore prognosis varied strongly by histologic subtypes and stage, with age-adjusted 5-year RS ranging from 43% (for sarcoma) to 94% (for squamous metaplasia), and reaching 91% for localized, 51% for regional, and 20% for distant stage. Except for age group 65-74 years, no significant improvement in survival was seen during the recent 5-year period under investigation. In this comprehensive population-based survival analysis of patients with endometrial cancer from Germany, prognosis of endometrial cancer moderately varied by age, and strongly varied by histology and stage. While prognosis is rather good overall, further improvement in 5-year relative survival of endometrial cancer patients has been stagnating in the early 21st century.